Buradasınız

Comparison of levels of Myeloperoxidase, C-reactive protein and Uric acid in patients of Stable and Unstable angina

Journal Name:

Publication Year:

Abstract (2. Language): 
Background: Coronary artery disease (CAD) is the leading cause of morbidity & mortality worldwide and comprises mainly stable angina, unstable angina & acute myocardial infarction . In the present study, we investigated plasma myeloperoxidase (MPO) level along with uric acid and C-reactive protein (CRP) in patients with stable and unstable angina. Methods: A total of 150 subjects were recruited and categorized into control group (n=50), stable angina (SA) group (n=50), unstable angina group (n=50). Plasma myeloperoxidase level was measured by a modified sandwich ELISA assay, uric acid was measured by enzymatic colorimetric reagents, CRP was measured by latex turbidity method assay Results: Plasma Myeloperoxidase (MPO) levels were significantly increased in unstable angina (340.94 ± 45.28) and stable angina (283.26 ± 30.68) as compared to control mean value (112.12 ± 29.07ng/ml). CRP was significantly raised in stable angina [3.73 ± 0.72], and in unstable angina [18.22 ± 5.75] as compared to control mean value [1.39 ± .643mg/l]. While serum uric acid levels were also significantly increased in unstable angina [5.58 ± 0.76], and stable angina [3.55 ± 0.62], when compared with control mean value of uric acid [2.52 ± 0.51mg/dl].The values of MPO,CRP & Uric acid were also significantly higher in unstable angina as compared to stable angina . Conclusion: Myeloperoxidase level is increased in stable and unstable angina patients and this increase is statistically significant when compared to the control group. Also this increase was in accordance with increase in other inflammatory marker like serum CRP and serum uric acid. Similarly these values were also higher in unstable than stable angina. Hence myeloperoxidase serves as a marker of the inflammation.
FULL TEXT (PDF): 
897-902

REFERENCES

References: 

1. Agner, K. Myeloperoxidase. Advances in Enzymology 3 (1943) 137-148.
2. Klebanoff, S.J., Myeloperoxidase: friend and foe. J Leukoc Biol, 2005; 77(5): p. 598- 625.
3. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340:115–126.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-
1695.
5. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;
25:1102–11.
6. Brennan ML, Penn MS, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J
Med. 2003;349:1595–604.
Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 897-902
902
www.ijbamr.com
7. Roman RM, Camargo PV, et al. Prognostic value of myeloperoxidase in coronary artery disease:
comparison of unstable and stable angina patients. Coron Artery Dis. 2010; 21:129–36.
8. Betty S. van der Veen, Menno P.J. de Winther, and Peter Heeringa. Myeloperoxidase: Molecular
Mechanisms of Action and Their Relevance to Human Health and Disease. Antioxidants & Redox Signaling.
November 2009, Vol. 11, No. 11: 2899-2937
9. Blake GJ, Ridker PM.C-reactive protein and other inflammatory risk markers in acute coronary syndromes.
J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):37S-42S.
10. Methods Enzymol 233, 502 (1994)
11. Inflammmation: Basic Principles and Clinical Correlates, Raven Press, New York (1988); p. 391
12. World Health Organization Web site. http://www.WHO.int. Accessed March 26, 2009.
13. Rosamond W, Flegal K, and Friday G; "Heart disease and stroke statistics--update: a report from the
American Heart Association Statistics Committee and Stroke Statistics Subcommittee" Circulation 2007;
115 (5): 69–171.
14. Heslop CL, Frohlich JJ, Hill JS, et al. Myeloperoxidase and C-reactive protein have combined utility for
long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010;
55:1102–9.

Thank you for copying data from http://www.arastirmax.com